XPO1 and neoplasm: We therefore sought to characterize the expression of XPO1 in canine OS tumours and OS cell lines to determine if XPO1 inhibition represents a viable target for therapeutic intervention and determine the activity of verdinexor alone or in combination with doxorubicin in canine OS cell lines as a prelude to future clinical trials in dogs.